Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer (Q40236236)

Dataset for "Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine"

18 September 2017

2 references

Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine

title

Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer (English)

1 reference

18 September 2017

1 reference

Samuel K Kulp

1

1 reference

18 September 2017

Chang-Shi Chen

2

1 reference

18 September 2017

Da-Sheng Wang

3

1 reference

18 September 2017

Ching-Yu Chen

4

1 reference

18 September 2017

Ching-Shih Chen

5

1 reference

18 September 2017

language of work or name

English

0 references

publication date

1 September 2006

1 reference

18 September 2017

published in

Clinical Cancer Research

1 reference

18 September 2017

volume

12

1 reference

18 September 2017

issue

17

1 reference

18 September 2017

page(s)

5199-5206

1 reference

Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824.

18 September 2017

cites work

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-06-0429

Mechanisms of toxic damage to spermatogenesis

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-06-0429

Survivin as a target for new anticancer interventions

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-06-0429

Less invasive surgery for colon cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-06-0429

Regulation of distinct biological activities of the NF-kappaB transcription factor complex by acetylation

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-06-0429

Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 Dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-06-0429

Histone-deacetylase inhibitors: novel drugs for the treatment of cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-06-0429

Epigenetic changes in prostate cancer: implication for diagnosis and treatment

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-06-0429

Phenylbutyrate attenuates the expression of Bcl-X(L), DNA-PK, caveolin-1, and VEGF in prostate cancer cells

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-06-0429

The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-06-0429

Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-06-0429

Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-06-0429

Histone deacetylase inhibitors: understanding a new wave of anticancer agents

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-06-0429

Histone deacetylase inhibitors open new doors in cancer therapy

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-06-0429

Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-06-0429

Histone deacetylase and DNA methyltransferase in human prostate cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-06-0429

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-06-0429

Targeting histone deacetylase in cancer therapy

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-06-0429

Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-06-0429

The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-06-0429

Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-06-0429

Histone deacetylases, transcriptional control, and cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-06-0429

In vivo effects of histone-deacetylase inhibitor trichostatin-A on murine spermatogenesis

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-06-0429

Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-06-0429

Stat3 dimerization regulated by reversible acetylation of a single lysine residue

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-06-0429

3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-06-0429

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-06-0429

Histone deacetylases and cancer: causes and therapies

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-06-0429

Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-06-0429

Post-translational modification of p53 in tumorigenesis

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-06-0429

Duration of nuclear NF-kappaB action regulated by reversible acetylation

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-06-0429

Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-06-0429

Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-06-0429

Histone deacetylase inhibitors differentially mediate apoptosis in prostate cancer cells

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-06-0429

Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-06-0429

Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-06-0429

Nuclear accumulation of histone deacetylase 4 (HDAC4) coincides with the loss of androgen sensitivity in hormone refractory cancer of the prostate

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-06-0429

Inhibition of histone deacetylases by chlamydocin induces apoptosis and proteasome-mediated degradation of survivin

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-06-0429

Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-06-0429

Inhibitors of histone deacetylase as new anticancer agents

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-06-0429

Molecular sequelae of histone deacetylase inhibition in human malignant B cells

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-06-0429

Identifiers

DOI

10.1158/1078-0432.CCR-06-0429

1 reference

18 September 2017

1 reference